Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors

INTRODUCTION: Until recently, adjuvant treatment options for higher stage resectable cutaneous melanoma were limited. Two studies with a similar set-up, published 2017, led to registration of targeted therapy for BRAF-mutated melanoma with dabrafenib and trametinib as well as of the immunotherapy wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahler, Steffen, Müller, Alfred, Fuchs, Sabine, von der Schulenburg, Johann-Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780795/
https://www.ncbi.nlm.nih.gov/pubmed/35059911
http://dx.doi.org/10.1186/s13561-021-00347-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780795/
https://www.ncbi.nlm.nih.gov/pubmed/35059911
http://dx.doi.org/10.1186/s13561-021-00347-7

Ejemplares similares